Skip to main content
Medical information Clinical review pending

Cytogenetics

FISH ROS1 6q22 Rearrangement Test

The FISH ROS1 6q22 Rearrangement Test detects specific genetic changes in the ROS1 gene, often found in certain cancers like non-small cell lung cancer. This information helps doctors choose the most effective treatment.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue. A completed Chromosome & FISH analysis Requisition Form (Form 17) is required.
Results
Reports are typically available within 4 working days after sample receipt, provided the sample is submitted by 4 PM daily.
Preparation
No specific patient preparation is required. Ensure the tissue block is properly labeled and accompanied by the completed requisition form.
Test priceKSh 17,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FISH ROS1 6q22 Rearrangement Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of non-small cell lung cancer (NSCLC)
  • ✓Identification of ROS1 gene rearrangements
  • ✓Guiding targeted therapy selection
  • ✓Prognosis assessment in certain cancers
  • ✓Patients with suspected lung cancer symptoms
  • ✓Patients with advanced or metastatic cancer
02

In plain language

What this test helps you understand

This test helps identify specific genetic alterations (ROS1 rearrangements) in cancer cells. This information is crucial for determining eligibility for targeted therapies and guiding personalized cancer treatment strategies, particularly in non-small cell lung cancer.
The FISH ROS1 6q22 Rearrangement Test is a specialized diagnostic tool used in oncology. It uses Fluorescence In Situ Hybridization (FISH) technology to identify rearrangements in the ROS1 gene. These genetic alterations are linked to specific types of cancer. Identifying these changes is important for guiding treatment decisions.

This test specifically looks for ROS1 gene rearrangements. These genetic changes can affect how cancer develops and progresses, particularly in non-small cell lung cancer (NSCLC). Detecting these alterations allows healthcare providers to tailor treatment strategies to the specific genetic makeup of the tumor.

Patients diagnosed with lung cancer, or those with symptoms like a persistent cough, chest pain, unexplained weight loss, or shortness of breath, may benefit from this test. It can also be recommended for individuals with a family history or other risk factors for lung cancer.

Taking this test can help identify genetic alterations influencing treatment choices, enabling oncologists to create personalized treatment plans. This can lead to more effective therapies and improved patient outcomes. Discussing the results with your oncologist is crucial to understand their implications for your care.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the tissue block is properly labeled and accompanied by the completed requisition form.
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue. A completed Chromosome & FISH analysis Requisition Form (Form 17) is required.
MethodologyFluorescence In Situ Hybridization (FISH)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific ROS1 rearrangements. It does not detect all possible genetic alterations associated with cancer. Results must be interpreted in the context of the patient's clinical presentation and other diagnostic findings. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test uses FISH technology to detect specific genetic rearrangements in the ROS1 gene, which can be associated with certain types of cancer, particularly lung cancer.
Identifying ROS1 rearrangements helps doctors determine if a patient might benefit from specific targeted therapies, leading to more personalized and potentially effective treatment.
A formalin-fixed paraffin-embedded (FFPE) tissue block containing tumor cells is required. The block should contain at least 10% tumor tissue.
Results are typically available within 4 working days after the sample is received by the laboratory, provided it is submitted by 4 PM daily.
A positive result indicates the presence of ROS1 rearrangements. Your doctor will interpret this result in the context of your overall health and cancer diagnosis to guide treatment decisions.
No specific preparation is needed from the patient for this test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp